OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference
OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on treating neuropathic corneal pain and inflammatory dry eye disease, announces its participation in the 4th Annual Virtual BTIG Ophthalmology Day on December 2nd, 2024. CEO Gary S. Jacob will engage in one-on-one meetings and lead a fireside chat from 2:40-3:15pm.
The event will feature over 20 medical technology and biotechnology companies, discussing latest developments in ophthalmic technologies and therapeutics. OKYO is developing treatments for NCP, which currently lacks FDA-approved therapies, and DED, representing a multi-billion-dollar market opportunity.
OKYO Pharma (NASDAQ: OKYO), una società biofarmaceutica in fase clinica focalizzata sul trattamento del dolore corneale neuropatico e della malattia infiammatoria dell'occhio secco, annuncia la sua partecipazione al 4° Annual Virtual BTIG Ophthalmology Day il 2 dicembre 2024. Il CEO Gary S. Jacob parteciperà a incontri individuali e condurrà una conversazione informale dalle 14:40 alle 15:15.
L'evento presenterà oltre 20 aziende nel campo della tecnologia medica e della biotecnologia, discutendo gli ultimi sviluppi nelle tecnologie e nei trattamenti oftalmici. OKYO sta sviluppando trattamenti per il dolore corneale neuropatico, per il quale attualmente non esistono terapie approvate dalla FDA, e per la malattia dell'occhio secco, rappresentando un'opportunità di mercato di diversi miliardi di dollari.
OKYO Pharma (NASDAQ: OKYO), una empresa biofarmacéutica en etapa clínica centrada en el tratamiento del dolor corneal neuropático y la enfermedad inflamatoria del ojo seco, anuncia su participación en el 4° Día Anual Virtual de Oftalmología de BTIG el 2 de diciembre de 2024. El CEO Gary S. Jacob participará en reuniones uno a uno y dirigirá una charla informal de 14:40 a 15:15.
El evento contará con más de 20 empresas de tecnología médica y biotecnología, discutiendo los últimos desarrollos en tecnologías y tratamientos oftálmicos. OKYO está desarrollando tratamientos para el dolor corneal neuropático, que actualmente no tiene terapias aprobadas por la FDA, y para la enfermedad del ojo seco, representando una oportunidad de mercado de varios miles de millones de dólares.
OKYO Pharma (NASDAQ: OKYO)는 신경병성 각막 통증 및 염증성 안구 건조증 치료에 주력하는 임상 단계의 생명공학 기업으로, 2024년 12월 2일 제4회 연례 가상 BTIG 안과의 날에 참가한다고 발표했습니다. CEO 게리 S. 제이콥은 일대일 회의에 참석하고 오후 2시 40분부터 3시 15분까지 난방담화를 진행할 예정입니다.
이 행사는 20개 이상의 의료 기술 및 생명공학 기업이 참여하여 안과 기술 및 치료법의 최신 개발 사항에 대해 논의하는 자리입니다. OKYO는 현재 FDA 승인이 없는 NCP 및 수십억 달러 규모의 시장 기회를 나타내는 DED에 대한 치료제를 개발하고 있습니다.
OKYO Pharma (NASDAQ: OKYO), une entreprise biopharmaceutique en phase clinique axée sur le traitement de la douleur cornéenne neuropathique et de la maladie inflammatoire de l'œil sec, annonce sa participation au 4ème BTIG Ophthalmology Day virtuel annuel le 2 décembre 2024. Le PDG Gary S. Jacob participera à des réunions en tête-à-tête et animera une discussion informelle de 14h40 à 15h15.
L'événement comptera plus de 20 entreprises de technologie médicale et de biotechnologie, discutant des derniers développements en matière de technologies et de thérapies ophtalmiques. OKYO développe des traitements pour le NCP, qui ne dispose actuellement d'aucune thérapie approuvée par la FDA, et le DED, représentant une opportunité de marché de plusieurs milliards de dollars.
OKYO Pharma (NASDAQ: OKYO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung von neuropathischen Hornhautschmerzen und entzündlichen trockenen Augen konzentriert, kündigt seine Teilnahme am 4. jährlichen virtuellen BTIG Augenärztetag am 2. Dezember 2024 an. CEO Gary S. Jacob wird an Einzelgesprächen teilnehmen und von 14:40 bis 15:15 Uhr ein informelles Gespräch leiten.
Veranstaltung wird über 20 Unternehmen aus dem Bereich Medizintechnik und Biotechnologie präsentieren, die über die neuesten Entwicklungen in der Augenheilkunde und Therapeutika diskutieren. OKYO entwickelt Behandlungen für NCP, für die es derzeit keine von der FDA zugelassenen Therapien gibt, und DED und stellt eine Marktchance von mehreren Milliarden Dollar dar.
- None.
- None.
LONDON and NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that its CEO, Gary S. Jacob, Ph.D., will be participating in one on one meetings and a fireside chat at the 4th Annual Virtual BTIG Ophthalmology Day on Monday, December 2nd, 2024. More than 20 public and private medical technology and biotechnology companies will be participating in BTIG’s event. Panel discussion topics will include exploring the latest developments and trends within ophthalmic medical technologies and therapeutics.
Presentation Information:
Event: 4th Annual BTIG Ophthalmology Day
Participant: Dr. Gary S. Jacob, CEO of OKYO Pharma
Date: Monday, December 2, 2024
Fireside Chat: 2:40-3:15pm
For more information about the event, email uscorporateaccess@btig.com. Please note that participants must be pre-registered to attend. To access BTIG insights, contact a firm representative or log in to www.btigresearch.com.
About NCP
Neuropathic corneal pain (NCP) is a condition that causes pain and sensitivity of the eyes, face, or head. The exact cause of NCP is unknown but thought to result from nerve damage to the cornea combined with inflammation. NCP, which can exhibit as a severe, chronic, or debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated by various topical and systemic treatments in an off-label fashion. There are no approved commercial treatments currently available for this condition.
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 showed clear statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-masked, placebo-controlled trial of OK-101 to treat DED, and is presently being evaluated in a randomized, placebo-controlled, double-masked Phase 2 trial to treat 48 NCP patients.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of NCP and DED, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat NCP and inflammatory DED. In addition to the recently completed Phase 2 trial of OK-101 to treat DED patients, OKYO is also evaluating OK-101 to treat NCP patients with the just announced opening of a Phase 2 trial to treat the debilitating conditions of NCP. For further information, please visit www.okyopharma.com.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
When is OKYO Pharma participating in the BTIG Ophthalmology Conference 2024?
What medical conditions is OKYO Pharma (NASDAQ: OKYO) developing treatments for?
How many companies are participating in the 2024 BTIG Ophthalmology Conference?
